Citi upgraded Glaukos (GKOS) to Buy from Neutral with a price target of $162, up from $132. Glaukos appears to have successfully launched iDose, and it is now executing on its broader portfolio, the analyst tells investors in a research note. With iDose sales likely inflecting next year along with a steady cadence of catalysts, Citi upgraded the shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks